Company
Pf Prism Cv
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
16
15 still marketed
Novel approvals
10
Approvals since 2021
12
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Xeljanz new use Mar 6, 2026
- Xeljanz new use Oct 16, 2025
- Xeljanz new use Feb 21, 2025
- Bosulif approved Priority reviewOrphanSep 26, 2023
- Bosulif new use Priority reviewOrphanSep 26, 2023
- Xalkori approved OrphanSep 7, 2023
- Xalkori new use OrphanSep 7, 2023
- Inlyta new use Sep 22, 2022
- Xalkori new use Priority reviewOrphanJul 14, 2022
- Xeljanz new use Dec 14, 2021
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (15)
Newest FDA action first.
- Xeljanz Tofacitinib Citrate · 2012
- Bosulif Bosutinib Monohydrate · 2023
- Bosulif Bosutinib Monohydrate · 2012
- Vfend Voriconazole · 2002
- Vfend Voriconazole · 2002
- Vfend Voriconazole · 2003
- Chantix Varenicline Tartrate · 2006
- Tygacil Tigecycline · 2005
- Inlyta Axitinib · 2012
- Xalkori Crizotinib · 2023
- Xalkori Crizotinib · 2011
- Pristiq Desvenlafaxine Succinate · 2008
- Rapamune Sirolimus · 2000
- Rapamune Sirolimus · 1999
- Torisel Temsirolimus · 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.